It is also noteworthy that several current clinical trials (NCT04177810, NCT02907099) in pancreatic cancer include anti-PD-1/PD-L1 therapies in conjunction to anti-CXCR4 therapies. This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.